Kiniksa Pharmaceuticals, Ltd.
KNSANASDAQHealthcare● Active
$49.04
+$0.62(+1.28%)
Market Cap$3.7B
P/E Ratio—
52W High$59.87
52W Low$26.27
Kiniksa Pharmaceuticals, Ltd. (KNSA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KNSA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.68B | $0.42B | $0.27B | $0.22B | $0.04B |
| Cost of Revenue | $0.31B | $0.06B | $0.06B | $0.02B | $0.01B |
| Gross Profit | $0.37B | $0.36B | $0.21B | $0.20B | $0.03B |
| Gross Margin %(computed) | 54.63% | 85.61% | 79.09% | 89.60% | 76.39% |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.11B | $0.08B | $0.07B | $0.10B |
| G&A Expenses | $0.00B | $0.16B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.29B | $0.41B | $0.24B | $0.19B | $0.19B |
| Operating Income | $0.08B | ($0.05B) | ($0.03B) | $0.01B | ($0.16B) |
| Operating Margin %(computed) | 11.40% | -10.78% | -9.32% | 4.44% | -406.38% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.09B | ($0.04B) | ($0.02B) | $0.01B | ($0.16B) |
| Income Tax Expense | $0.03B | $0.01B | ($0.03B) | ($0.17B) | $0.00B |
| Net Income | $0.06B | ($0.04B) | $0.01B | $0.18B | ($0.16B) |
| Net Margin %(computed) | 8.71% | -10.21% | 5.21% | 83.28% | -409.72% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.80 | $-0.60 | $0.20 | $2.64 | $-2.30 |
| Wtd Avg Shares | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B |
| EBITDA | $0.09B | ($0.04B) | ($0.02B) | $0.01B | ($0.15B) |
| EBITDA Margin %(computed) | 13.35% | -10.38% | -8.46% | 5.53% | -400.27% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Kiniksa Pharmaceuticals, Ltd. data
About Kiniksa Pharmaceuticals, Ltd. (KNSA) Income Statement
Kiniksa Pharmaceuticals, Ltd. (KNSA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KNSA reported revenue of $0.68B, gross profit of $0.37B (gross margin 54.63%), and net income of $0.06B — a net profit margin of 8.71%.
Frequently asked questions
KNSA · 4 questionsKiniksa Pharmaceuticals, Ltd. (KNSA) reported revenue of $0.68B for 2025, up 60.1% year-over-year.
KNSA revenueKNSA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08